Skip to content

Based on my review of the GO-CAM model (62b4ffe300005014) and the proteins involved, I'll now provide a comprehensive review:

GO-CAM Model Review: Poxvirus-OPG176 inhibition of host TLR4 signaling (Human-Poxvirus)

Model Summary

This model (gomodel:62b4ffe300005014) represents the mechanism by which Vaccinia virus protein OPG176 (also known as A46R) inhibits TLR4 signaling in human host cells. The model contains four key activities:

  1. TLR4 (UniProtKB:O00206) - signaling receptor activity (GO:0038023)
  2. TIRAP (UniProtKB:P58753) - molecular adaptor activity (GO:0060090)
  3. MYD88 (UniProtKB:Q99836) - molecular adaptor activity (GO:0060090)
  4. Vaccinia virus OPG176 (UniProtKB:P26672) - protein sequestering activity (GO:0140311)

The causal flow in the model shows: - TLR4 directly positively regulates (RO:0002629) TIRAP activity - TIRAP directly positively regulates (RO:0002629) MYD88 activity - Vaccinia virus OPG176 directly negatively regulates (RO:0002630) TIRAP activity

Strengths of the Model

  1. Well-supported evidence: Each activity and relationship in the model is supported by appropriate experimental evidence with citations to relevant publications.

  2. Clear biological mechanism: The model correctly represents how Vaccinia virus protein OPG176 interferes with the TLR4 signaling pathway by inhibiting the TIRAP adaptor protein, thereby preventing downstream signaling.

  3. Correct subcellular locations: The model correctly places TLR4 in the plasma membrane (GO:0005886) and TIRAP/MYD88 at the cytoplasmic side of the plasma membrane (GO:0031234).

  4. Proper use of causal relations: The model correctly uses RO:0002629 (directly positively regulates) for the activating relationships and RO:0002630 (directly negatively regulates) for the inhibitory relationship.

  5. Appropriate biological process annotations: Each activity is properly associated with a relevant biological process - TLR4, TIRAP, and MYD88 are all part of the TLR4 signaling pathway (GO:0034142), while the viral protein is part of the symbiont-mediated suppression of host toll-like receptor signaling pathway (GO:0039722).

Areas for Improvement

There are no significant issues with the model, but here are some minor points that could enhance its clarity and completeness:

  1. CD14 role: The model doesn't include CD14, which often serves as a co-receptor for LPS binding to TLR4. While not essential, adding CD14 and its interaction with LPS could provide more context for TLR4 activation.

  2. Downstream effects: The model could be extended to show the downstream effects of MYD88 inhibition, such as reduced NF-κB activation and cytokine production, to provide a more complete picture of the pathway disruption consequences.

  3. Detailed mechanism of OPG176: While the model correctly shows OPG176 inhibiting TIRAP, it doesn't detail the mechanism (protein sequestration). The literature indicates OPG176 directly binds to and sequesters TIRAP, preventing its interaction with TLR4. This mechanism could be more explicitly represented.

Consistency with Literature

The model aligns well with the published literature:

  1. TLR4 signaling: The basic TLR4 signaling pathway via TIRAP and MYD88 is correctly represented, consistent with the referenced papers (PMID:15618008, PMID:12055629).

  2. OPG176 inhibition: The viral inhibition mechanism is correctly shown, with OPG176 targeting TIRAP (PMID:22593572). This is consistent with the role of vaccinia virus in suppressing host immune responses.

  3. Subcellular localization: The model correctly places TLR4 at the plasma membrane and the adaptors at the extrinsic component of cytoplasmic side of plasma membrane, consistent with literature on TLR4 signaling.

Consistency with GO-CAM Best Practices

The model follows the GO-CAM best practices for representing complexes and molecular activities:

  1. Molecular functions: Each protein is annotated with an appropriate molecular function.

  2. Causal relationships: The model uses the correct causal relationship predicates for the depicted process.

  3. Cellular compartments: The model correctly specifies the cellular components where each activity occurs.

  4. Evidence codes: Appropriate evidence codes are used for each assertion in the model.

Conclusion

This is a well-constructed GO-CAM model that accurately represents the mechanism by which Vaccinia virus protein OPG176 inhibits TLR4 signaling in human host cells. The model is supported by appropriate evidence, follows GO-CAM best practices, and is consistent with the published literature on TLR4 signaling and viral immune evasion strategies.

The model successfully illustrates a viral immune evasion strategy whereby a viral protein (OPG176) interferes with the host innate immune response by targeting a key adaptor molecule (TIRAP) in the TLR4 signaling pathway, preventing downstream signaling events that would normally lead to inflammatory cytokine production and antiviral responses.